Market News

The pace of activity across China’s vast economy unexpectedly slowed last month. Manufacturing slid into contraction, services produced an unexpectedly low result, and the overall measure showed the lowest rate of expansion in 11 months. The official survey covers large companies. Later today, the unofficial Caixin survey, which covers small and medium businesses, will be […]

The $18.7 billion Canadian-US bid for Origin Energy (ASX:ORG) appears to be in jeopardy and may require a higher offer price, as Origin’s largest shareholder, AustralianSuper, has rejected the current deal. AustralianSuper, which owns 13.7% of Origin, has indicated its intention to decline the offer from the Canadian infrastructure giant Brookfield and US energy investor

With the resolution of Chinese wine tariffs on the horizon in the coming weeks, Treasury Wine Estates is making a significant move in the US alcohol sector. The company has a history of major deals in the US, notably the acquisition of Beringer Estates when it was under Foster’s control. On Tuesday, the company unveiled

The S&P/ASX 200 is trading 0.18 per cent higher at 6,785.30. Futures The SPI futures are up 12 points. Best and worst performers The best-performing sector is REITs, up 1.56 per cent. The worst-performing sector is Materials, down 1.09 per cent. The best-performing large cap is Qantas Airways (ASX:QAN), trading 3.13 per cent higher at

Chimeric Therapeutics (ASX:CHM), announced that the FDA has cleared the Investigational New Drug application of CHM 2101, Chimeric’s first in class CDH17 CAR T cell therapy for gastrointestinal cancers.  Michael R. Bishop, Professor of Medicine and Director at the University of Chicago commented “I am really excited about the planned Phase 1 clinical trial of

At noon, the S&P/ASX 200 is 0.37 per cent higher at 6,798. The SPI futures are pointing to a rise of 22 points. Asia-Pacific markets were mixed with markets awaiting monetary policy decisions by the Bank of Japan. The Bank of Japan is expected to finish its policy meeting later today Australian time. The key

Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company’s drug candidates, highlighting promising data from the  2023 ESMO Congress. Paul Sanger: I’m Paul Sanger for the Finance News Network, and today we’re talking with Immutep (ASX:IMM), and they have a market cap of $380m. Immutep is a clinical-stage biotech company

Stocks rallied on Monday, with the S&P 500 ending the day out of correction territory, as traders kicked off a big week filled with a Federal Reserve rate decision, jobs report and Apple’s earnings. The Dow Jones Industrial Average gained 511.37 points, or 1.58 per cent, to 32,928.96. The 30-stock index registered its best day

On Monday, the ASX experienced a decline of 0.8 percent at 6772.9 points. This drop below 6800 points marked the first time it had done so this year and is its lowest point since October 2022. The decline was influenced by renewed fears that the conflict between Israel and Hamas could escalate into a regional

Even though the economy is booming and job growth continues, inflation is slowing, leading the US Federal Reserve to refrain from raising interest rates this week. The Fed’s favored PCE inflation reading for September saw a slight increase, but rates are expected to remain unchanged after the two-day meeting early Thursday morning, Sydney time. There’s